Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Hypertrophic Cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, the sensation of rapid, fluttering, or pounding heartbeats, and heart murmur. HCM usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.
The HCM pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HCM and features dormant and discontinued projects.
HCM Pipeline Drugs Market Segmentation by Targets
Some of the targets of the HCM pipeline drugs market are Myosin, Myosin Binding Protein C Cardiac Type, cGMP Inhibited 3′,5′ Cyclic Phosphodiesterase A, G Protein Coupled Receptor Kinase 5, Myocyte Specific Enhancer Factor 2, Neprilysin, Short Transient Receptor Potential Channel 6, and Type 1 Angiotensin II Receptor.
HCM Pipeline Drugs Market Analysis, by Targets
For more HCM pipeline drugs market target insights, download a free report sample
HCM Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the HCM pipeline drugs market are Myosin Inhibitor, Myosin Binding Protein C Cardiac Type Activator, cGMP Inhibited 3′,5′ Cyclic Phosphodiesterase A Inhibitor, G Protein Coupled Receptor Kinase 5 Inhibitor, Myocyte Specific Enhancer Factor 2 Inhibitor, Neprilysin Inhibitor, Short Transient Receptor Potential Channel 6 Blocker, and Type 1 Angiotensin II Receptor Antagonist.
HCM Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the HCM pipeline drugs market, download a free report sample
HCM Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the HCM pipeline drugs market are oral and intravenous.
HCM Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the HCM pipeline drugs market, download a free report sample
HCM Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the HCM pipeline drugs market are Small Molecule, Gene Therapy, Antisense Oligonucleotide, Recombinant Peptide.
HCM Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the HCM pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the HCM pipeline drugs market are Bristol-Myers Squibb Co, DiNAQOR AG, Cytokinetics Inc, Cardior Pharmaceuticals GmbH, Algomedix Inc, BioMarin Pharmaceutical Inc, C&C BioPharma LLC, Celltrion Inc, Edgewise Therapeutics Inc, and Genome Biologics UG.
HCM Pipeline Drugs Market Analysis, by Companies
To know more about the HCM pipeline drugs market companies, download a free report sample
HCM Pipeline Drugs Market Report Overview
| Key Targets | Myosin, Myosin Binding Protein C Cardiac Type, cGMP Inhibited 3′,5′ Cyclic Phosphodiesterase A, G Protein Coupled Receptor Kinase 5, Myocyte Specific Enhancer Factor 2, Neprilysin, Short Transient Receptor Potential Channel 6, and Type 1 Angiotensin II Receptor |
| Key Mechanism of Actions | Myosin Inhibitor, Myosin Binding Protein C Cardiac Type Activator, cGMP Inhibited 3′,5′ Cyclic Phosphodiesterase A Inhibitor, G Protein Coupled Receptor Kinase 5 Inhibitor, Myocyte Specific Enhancer Factor 2 Inhibitor, Neprilysin Inhibitor, Short Transient Receptor Potential Channel 6 Blocker, and Type 1 Angiotensin II Receptor Antagonist |
| Key Routes of Administration | Oral and Intravenous |
| Key Molecule Types | Small Molecule, Gene Therapy, Antisense Oligonucleotide, Recombinant Peptide |
| Key Companies | Bristol-Myers Squibb Co, DiNAQOR AG, Cytokinetics Inc, Cardior Pharmaceuticals GmbH, Algomedix Inc, BioMarin Pharmaceutical Inc, C&C BioPharma LLC, Celltrion Inc, Edgewise Therapeutics Inc, and Genome Biologics UG |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy.
- Reviews of pipeline therapeutics for HCM by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in HCM therapeutics and enlists all their major and minor projects.
- Evaluation of HCM therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with the potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding HCM pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
C&C BioPharma LLC
Cardior Pharmaceuticals GmbH
Celltrion Inc
Cytokinetics Inc
DiNAQOR AG
Edgewise Therapeutics Inc
Genome Biologics UG
Haya Therapeutics SA
Igia Pharmaceuticals Inc
Imbria Pharmaceuticals Inc
Invivosciences Inc
Jaan Biotherapeutics LLC
Lead Discovery Center GmbH
LEXEO Therapeutics LLC
Novartis AG
Saliogen Therapeutics Inc
Tenaya Therapeutics Inc
Toa Eiyo Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the HCM pipeline drugs market?
Some of the key targets of the HCM pipeline drugs market are Myosin, Myosin Binding Protein C Cardiac Type, cGMP Inhibited 3′,5′ Cyclic Phosphodiesterase A, G Protein Coupled Receptor Kinase 5, Myocyte Specific Enhancer Factor 2, Neprilysin, Short Transient Receptor Potential Channel 6, and Type 1 Angiotensin II Receptor.
-
What are the key mechanisms of action in the HCM pipeline drugs market?
Some of the key mechanisms of action in the HCM pipeline drugs market are Myosin Inhibitor, Myosin Binding Protein C Cardiac Type Activator, cGMP Inhibited 3′,5′ Cyclic Phosphodiesterase A Inhibitor, G Protein Coupled Receptor Kinase 5 Inhibitor, Myocyte Specific Enhancer Factor 2 Inhibitor, Neprilysin Inhibitor, Short Transient Receptor Potential Channel 6 Blocker, and Type 1 Angiotensin II Receptor Antagonist.
-
What are the key routes of administration in the HCM pipeline drugs market?
The key routes of administration in the HCM pipeline drugs market are oral and intravenous.
-
What are the key molecule types in the HCM pipeline drugs market?
The molecule types in the HCM pipeline drugs market are Small Molecule, Gene Therapy, Antisense Oligonucleotide, Recombinant Peptide.
-
Which are the key companies in the HCM pipeline drugs market?
Some of the key companies in the HCM pipeline drugs market are Bristol-Myers Squibb Co, DiNAQOR AG, Cytokinetics Inc, Cardior Pharmaceuticals GmbH, Algomedix Inc, BioMarin Pharmaceutical Inc, C&C BioPharma LLC, Celltrion Inc, Edgewise Therapeutics Inc, and Genome Biologics UG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Cardiovascular reports